Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Percept Mot Skills ; 44(2): 445-6, 1977 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-866047

RESUMEN

This study investigated the effects of a Developmental Learning Program upon self-concept of 40 children having trouble in school. While preliminary in nature, the results suggest that such a program may have a beneficial effect.


Asunto(s)
Discapacidades para el Aprendizaje/rehabilitación , Educación Compensatoria , Instituciones Académicas , Autoimagen , Niño , Conducta Infantil , Humanos
3.
J Hepatol ; 34(6): 903-10, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11451175

RESUMEN

BACKGROUND/AIMS: Treatment with hepatitis B virus immune globulins (HBIG) or lamivudine has reduced the rate of hepatitis B recurrence after liver transplantation to approximately 50%. METHODS: To further decrease hepatitis B recurrence, 33 hepatitis B virus (HBV)-related cirrhotic patients were treated with lamivudine before liver transplantation and with lamivudine together with low-dose HBIG (46 500 IU the first month followed by 5,000 lU/monthly) after surgery. RESULTS: While on lamivudine, serum HBV DNA level decreased significantly in all patients and in 11 (33%) the Child-Pugh score improved. Twenty-six patients were transplanted. Among the 25 who survived for longer than 12 months, only one (4%) experienced a hepatitis B recurrence over an average follow-up of 31 months, a rate significantly lower (P = 0.0002) than the 50% recurrence rate among a historical control group of 12 patients. However, low-level HBV replication was detected sporadically throughout the follow-up in 64% of patients. CONCLUSIONS: Over the medium-term, combined prophylaxis with lamivudine and HBIG significantly decreases the risk of hepatitis B recurrence after liver transplantation. Though low-level HBV infection recurred in two thirds of patients, the pathogenic expression of HBV was prevented.


Asunto(s)
Antivirales/uso terapéutico , Anticuerpos contra la Hepatitis B/uso terapéutico , Hepatitis B/prevención & control , Lamivudine/uso terapéutico , Cirrosis Hepática/cirugía , Trasplante de Hígado , Adulto , ADN Viral/sangre , Femenino , Hepatitis B/terapia , Hepatitis B/virología , Humanos , Inmunización Pasiva , Inmunoglobulinas/uso terapéutico , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/terapia , Trasplante de Hígado/efectos adversos , Masculino , Persona de Mediana Edad , Recurrencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA